secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2026-02-12T23:59:59+00:00
Accession:  0001493152-26-006428
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo to voluntarily delist from Nasdaq and deregister SEC; Q2 net loss $2.0M
-------------------------------------------------------------------------------

- Board approved voluntary delisting from Nasdaq and SEC deregistration; expects delisting effective Feb 27, 2026.
- Net loss of $2.0M ($0.05/shr) vs $2.5M ($0.09/shr) in same quarter prior year.
- Operating expenses flat at $2.6M; cash $9.0M plus $3.0M loan facility available.
- Lead candidate selonabant: IV formulation Phase 1 SAD study started Sep 2025; prioritizing pediatric pathway.
- Company cites cost savings from ending public reporting obligations as rationale for delisting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315226006428/0001493152-26-006428-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315226006428/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-006428

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer